Defibrotide

Defibrotide
Defibrotide
Clinical data
AHFS/Drugs.com International Drug Names
Pregnancy cat. X
Legal status Rx only (where available)
Routes oral, i.m., i.v.
Pharmacokinetic data
Bioavailability 58 - 70% orally (i.v. and i.m. = 100%)
Half-life t1/2-alpha = minutes; t1/2-beta = a few hours
Identifiers
CAS number 83712-60-1
ATC code B01AX01
DrugBank DB04932
UNII 438HCF2X0M YesY
KEGG D07423 YesY
Chemical data
Formula  ?
 YesY(what is this?)  (verify)

Defibrotide is a deoxyribonucleic acid derivative (single-stranded) derived from cow lung or porcine mucosa. It is an anticoagulant with a multiple mode of action (see below).

It has been used with antithrombin III.[1]

Contents

Pharmacokinetics

Defibrotide is available as an oral, intravenous, and intramuscular formulation. Its oral bioavailability is in the range of 58-70% of the parenteral forms. T1/2 alpha is in the range of minutes while T1/2 beta is in the range of hours in studies with oral radiolabelled defibrotide. These data suggest that defibrotide, in spite of its macromolecular nature, is absorbed well after oral administration. Due to the drug's short half-life, it is necessary to give the daily dose divided in 2 to 4 doses (see below).

Mode of action

The drug appears to prevent the formation of blood clots and to help dissolve blood clots by increasing levels of prostaglandin I2, E2, and prostacyclin, altering platelet activity, increasing tissue plasminogen activator (tPA-)function, and decreasing activity of tissue plasminogen activator inhibitor. Prostaglandin I2 relaxes the smooth muscle of blood vessels and prevents platelets from adhering to each other. Prostaglandin E2 at certain concentrations also inhibits platelet aggregation. Moreover, the drug provides additional beneficial anti-inflammatory and antiischemic activities as recent sudies have shown. It is yet unclear, if the latter effects can be utilized clinically (e.g., treatment of ischemic stroke).

Unlike heparin and warfarin, defibrotide appears to have a relatively mild anticoagulant activity, which may be beneficial in the treatment of patients at high risk of bleeding complications. Nevertheless, patients with known bleeding disorders (e.g., hemophilia A) or recent abnormal bleedings should be treated cautiously and under close medical supervision.

The drug was marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a variety of countries. It is currently not approved in the USA. The manufacturer is Gentium.

Usual indications

Defibrotide is used to treat or prevent a failure of normal blood flow (Veno-occlusive disease, VOD) in the liver of patients having had bone marrow transplants or received certain drugs such as oral estrogens, mercaptopurine, and many others. Without intensive treatment, VOD is often a fatal condition, leading to multiorgan failure. It has repeatedly been reported that defibrotide was able to resolve the condition completely and was well tolerated.

Other indications are: peripheral obliterative arterial disease, thrombophlebitis, and Raynaud's phenomenon. In very high doses, defibrotide is useful as treatment of acute myocardial infarction. The drug may also be used for the pre- and postoperative prophylaxis of deep venous thrombosis and can replace the heparin use during hemodialytic treatments.

It has been investigated for use in treatment of chronic venous insufficiency.[2]

Potential indications in the future

Other recent preclinical studies have demonstrated that defibrotide used in conjunction with Granulocyte Colony-Stimulating Factor (rhG-CSF) significantly increases the number of Peripheral Blood Progenitor Cells (Stem cells). The benefit of this increase in stem cells may be crucial for a variety of clinical indications, including graft engineering procedures and gene therapy programs. This would expand the clinical usefulness of defibrotide to a complete distinct area.

Very recently (since early 2006) combination therapy trials (phase I/II) with defibrotide plus melphalan, prednisone, and thalidomide in patients with multiple myeloma have been conducted. The addition of defibrotide is expected to decrease the myelosuppressive toxicity of melphalan. However, is too early for any definitive results at that stage.

Cautions and contraindications

  • The efficacy of the drug has been reported to be poorer in patients with diabetes mellitus.
  • Pregnancy: The drug should not be used during pregnancy, because adequate and well controlled human studies do not exist.
  • Lactation: No human data is available. In order to avoid damage to the newborn, the nursing mother should discontinue either the drug or breastfeeding, taking into account the importance of treatment to the mother.
  • Known Bleeding Disorders or Bleeding Tendencies having occurred recently: Defibrotide should be used cautiously. Before initiation of treatment, the usual coagulation values should be obtained as baseline and regularly controlled under treatment. The patient should be observed regularly regarding local or systemic bleeding events.

Side-effects

Increased bleeding and bruising tendency, irritation at the injection site, nausea, vomiting, heartburn, low blood pressure. Serious allergic reactions have not been observed so far.

Drug interactions

Use of heparin with defibrotide may increase the aPTT, reflecting reduced ability of the body to form a clot. Nothing is known about the concomitant application of other anticoagulants than heparin and dextran containing plasma-expanders, but it can be anticipated that the risk of serious bleeding will be increased considerably.


References

External links


Wikimedia Foundation. 2010.

Игры ⚽ Нужно решить контрольную?

Look at other dictionaries:

  • defibrotide — defibrotide. См. дефибротид. (Источник: «Англо русский толковый словарь генетических терминов». Арефьев В.А., Лисовенко Л.А., Москва: Изд во ВНИРО, 1995 г.) …   Молекулярная биология и генетика. Толковый словарь.

  • defibrotide — sal sódica de polidesoxiribonucleótidos obtenidos por hidrólisis controlada de ADN de pulmones de mamíferos que se utiliza para el tratamiento de desórdenes vaso oclusivos monografía [véase http://www.iqb.es/cbasicas/farma/farma04/d064.htm]… …   Diccionario médico

  • defibrotide — A substance that is being studied in the prevention of veno occlusive disease, a rare complication of high dose chemotherapy and stem cell transplantation in which small veins in the liver become blocked …   English dictionary of cancer terms

  • дефибротид — defibrotide дефибротид. Плазматический антагонист тромбина, участвующий в регуляции процесса свёртывания крови; представляет собой короткие одноцепочечные молекулы ДНК, ограниченные консенсусным гексапептидом ГГхТГГ; считается, что активность Д.… …   Молекулярная биология и генетика. Толковый словарь.

  • Hepatic veno-occlusive disease — Classification and external resources ICD 10 K76.5 OMIM 235550 Disease …   Wikipedia

  • Stem cell transplantation — Hematopoietic stem cell transplantation (HSCT) or bone marrow transplantation is a medical procedure in the field of hematology and oncology that involves transplantation of hematopoietic stem cells (HSC). It is most often performed for people… …   Wikipedia

  • Aspirin — Asprin redirects here. For the author, see Robert Asprin. Aspirin …   Wikipedia

  • Citrate — The citrate anion A citrat …   Wikipedia

  • Antiplatelet drug — An antiplatelet drug is a member of a class of pharmaceuticals that decreases platelet aggregation [DorlandsDict|nine/12901130|antiplatelet agent] and inhibits thrombus formation. They are effective in the arterial circulation, where… …   Wikipedia

  • Anticoagulant — An anticoagulant is a substance that prevents coagulation (clotting) of blood. A group of pharmaceuticals called anticoagulants can be used in vivo as a medication for thrombotic disorders. Some anticoagulants are used in medical equipment, such… …   Wikipedia

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”